Pip6a Ac-RXRRBRRXRYQFLIRXRBRXRB-acid, B is β-Alanine. X is Aminohexanoic acid

  • Description

  • Application Data

Description

PNA/PMO internalisation peptide 6a

See full description

Application Data

Catalogue number crb1000352
Molecular Weight 2425.45
Sequence (one letter code) Ac-RXRRBRRXRYQFLIRXRBRXRB-acid, B is β-Alanine. X is Aminohexanoic acid
Sequence (three letter code) Ac-Arg-[Ahx]-Arg-Arg-[β-Ala]-Arg-Arg-[Ahx]-Arg-Tyr-Gln-Phe-Leu-Ile-Arg-[Ahx]-Arg-[β-Ala]-Arg-[Ahx]-Arg-[β-Ala]-OH, β-Ala is β-Alanine and Ahx is Aminohexanoic acid
Molecular Weight 2425.45
Purity >95%
Storage -20°C
References

Betts et al (2012) Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol. Ther. Nucleic Acids 1 e38 PMID: 23344180

 

Hammond et al (2016) Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. PNAS 113(39) 10962 PMID: 27621445

Data Sheet Material Safety Data Sheet (MSDS)

Pip6a is part of a novel series of transduction peptides termed Pips (PNA/PMO internalisation peptides). Pip peptides were designed around an original R6-penetratin cell penetrating peptide (CPP) and are able to transport PNA/PMO molecules across cell membranes. Pip peptides can be covalently conjugated to PNAs/PMOs to deliver them to a variety of adult tissues, including liver, kidney, skeletal muscle, diaphragm, and heart.

Due to its ability to target the heart, pip6a has important implications for the development of therapeutic antisense oligonucleotide therapy using PMOs for diseases such as Duchenne muscular dystrophy (DMD). DMD causes progressive muscle weakening and often results in cardiac failure and death. Pip6a has also been studied for delivery of antisense oligonucleotide therapy in spinal muscular atrophy (SMA).

Pip6a

Cat No.Pack SizePriceQty.
£1,366.67
1mg£110.00
0.5mg£85.00
Bulk Quote